SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-027582
Filing Date
2024-03-07
Accepted
2024-03-07 07:05:09
Documents
16
Period of Report
2024-03-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K eypt-20240307.htm   iXBRL 8-K 38120
2 EX-99.1 eypt-ex99_1.htm EX-99.1 42902
3 GRAPHIC img96707757_0.jpg GRAPHIC 5406
4 GRAPHIC img96707757_1.jpg GRAPHIC 58848
5 GRAPHIC img96707757_2.jpg GRAPHIC 76664
  Complete submission text file 0000950170-24-027582.txt   393443

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT eypt-20240307.xsd EX-101.SCH 23897
17 EXTRACTED XBRL INSTANCE DOCUMENT eypt-20240307_htm.xml XML 4523
Mailing Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472
Business Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472 617-926-5000
EyePoint Pharmaceuticals, Inc. (Filer) CIK: 0001314102 (see all company filings)

IRS No.: 262774444 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51122 | Film No.: 24728132
SIC: 3826 Laboratory Analytical Instruments
(CF Office: 08 Industrial Applications and Services)